A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy

Niiranen, A.; Mattson, K.

doi:10.1097/00000421-198508000-00013

Cited by 41 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results similar to those described above have also been found showing the superiority of nabilone compared to prochlorperazine in lung cancer patients undergoing chemotherapy (Ahmedazi et al 1983; Niiranen and Mattson 1985), but the side effect profile of dizziness and disorientation demands careful patient monitoring. No difference was found between nabilone and metoclopramide in patients on cisplatin (Crawford and Buckman 1986), while nabilone has been found superior to alizapride in young patients with testicular cancer on cisplatin (Niederle 1986) and was superior to domperidone in another trial in which 70% of subjects were on cisplatin (Pomeroy et al 1986).…”

Section: Efficacy and Safety Of Nabilonesupporting

confidence: 75%

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

Ware¹

2008

TCRM

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) in cancer patients places a signifi cant burden on patients' function and quality of life, their families and caregivers, and healthcare providers. Despite the advances in preventing CINV, a substantial proportion of patients experience persistent nausea and vomiting. Nabilone, a cannabinoid, recently received Food and Drug Administration approval for the treatment of the nausea and vomiting in patients receiving cancer chemotherapy who fail to achieve adequate relief from conventional treatments. The cannabinoids exert antiemetic effects via agonism of cannabinoid receptors (CB1 and CB2). Clinical trials have demonstrated the benefi ts of nabilone in cancer chemotherapy patients. Use of the agent is optimized with judicious dosing and selection of patients.

show abstract

Section: Efficacy and Safety Of Nabilonesupporting

confidence: 75%

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

Ware¹

2008

TCRM

View full text Add to dashboard Cite

show abstract

“…In one trial rates of nausea and vomiting were 100% despite prochlorperazine46; chemotherapy was with cisplatin. In two trials, the nausea rate was 85% despite alizapride53 and 83% despite prochlorperazine54; again, the chemotherapy regimen contained cisplatin. Finally, in one trial 90% of controls receiving prochlorperazine vomited; chemotherapy was with moderately emetogenic drugs (cyclophosphamide, methotrexate, fluorouracil) 34…”

Section: Resultsmentioning

confidence: 99%

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic

Tramèr

Carroll²,

Campbell³

et al. 2001

BMJ

520

264

View full text Add to dashboard Cite

show abstract

“…Nabilone was found to be superior to placebo in 3 studies . A number of studies also compared single‐agent nabilone with active controls such as metoclopramide, prochlorperazine, domperidone, and alizapride, and found that nabilone was at least as effective and sometimes more effective than the control drug. However, nabilone was associated with more severe central nervous system side effects than the comparator drugs such as drowsiness, postural dizziness and hypotension, lightheadedness, euphoria, and, rarely, hallucinations …”

Section: Review Of Potential Medical Uses For Marijuana and Cannabinomentioning

confidence: 99%

Medical marijuana for cancer

Kramer

2014

CA A Cancer J Clinicians

117

101

View full text Add to dashboard Cite

Answer questions and earn CME/CNE Marijuana has been used for centuries, and interest in its medicinal properties has been increasing in recent years. Investigations into these medicinal properties has led to the development of cannabinoid pharmaceuticals such as dronabinol, nabilone, and nabiximols. Dronabinol is best studied in the treatment of nausea secondary to cancer chemotherapy and anorexia associated with weight loss in patients with acquired immune deficiency syndrome, and is approved by the US Food and Drug Administration for those indications. Nabilone has been best studied for the treatment of nausea secondary to cancer chemotherapy. There are also limited studies of these drugs for other conditions. Nabiximols is only available in the United States through clinical trials, but is used in Canada and the United Kingdom for the treatment of spasticity secondary to multiple sclerosis and pain. Studies of marijuana have concentrated on nausea, appetite, and pain. This article will review the literature regarding the medical use of marijuana and these cannabinoid pharmaceuticals (with emphasis on indications relevant to oncology), as well as available information regarding adverse effects of marijuana use.

show abstract

A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy

Cited by 41 publications

References 0 publications

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic

Medical marijuana for cancer

Contact Info

Product

Resources

About